Cox 2 inhibitors and the risk of cardiovascular thrombotic events

Irish Medical Journal

Volumn 105, Issue 4, 2012, Pages 12-

  Khan, M ^a   Fraser, A ^a  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; PARACOXIB; ROFECOXIB; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG INDICATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEART DEATH; HEART PROTECTION; HUMAN; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; STROKE; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT WITHDRAWAL;

EID: 84860212047     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat New Biol. 1971; 23:232-235
2. Kujubu DA, Fletcher BS, Varnam BC, Lim RW, Herschma HR. TISIO, a phorbol ester tumor promoter- inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologive. J Biol Chem. 1991; 266:12866-12872. Abstract
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvein TK, Schnitzner TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;3:1520-1528.
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;17:1092-1102.
5. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;13:1247-55
6. Arber N, Eagle CJ, Spicak J, R̂cz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps.PreSAP Trial Investigators. N Engl J Med. 2006;31:885-95.
7. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;17:1e33
8. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
9. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;20:1809-17.
10. Watson DJ, Rhodes T. Higher incidence of thromboembolic events among patients with rheumatoid arthritis vs. osteoarthritis, and vs. no arthritis, in the general practice research database (GPRD). Presented at EULAR 2001, European Congress of Rheumatology; June 13-16, 2001; Prague, Czech Republic. Abstract OP010.
11. Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Funk MJ, Weil J. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf. 2008;17:601-608
12. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators.Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;5:1028-35.
13. Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009;48:425-32. Epub 2009 Feb 17
14. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;17:1081-91. Epub 2005 Feb 15
15. Kearney PM et al "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials". BMJ 332 (7553): 1302-8. doi:10.1136/bmj.332.7553.1302.
16. Fosb̂'l EL, Folke F, Jacobsen S, Rasmussen JN Ŝ'rensen R, Schramm TK, Andersen SS, Rasmussen S, Poulsen HE, K̂'ber L, Torp-Pedersen C, Gislason GH. Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. Circ Cardiovasc Qual Outcomes. 2010 Jun 8. [Epub ahead of print]